Posted on

cannabidiol anxiety

While CBD oil had a characteristic smell and taste, all of the psychologists and the participants had been naive to the CBD oil as well as the placebo. The interview with them that was conducted after the completion of the study revealed that none of them noticed the difference between the two.

McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized control trial. Am. J. Psychiatry 175, 225–231. doi: 10.1176/appi.ajp.2017.17030325

Ethics Statement

The purpose of the current study was to pursue this issue further and to investigate the possible efficacy of CBD as at least an adjunctive option for intervention in people with SAD. While SAD has been classified into several subtypes so far (Antony and Rowa, 2008), here, the author concentrated the research on that with avoidant personality disorder because this subtype is the most commonly diagnosed and is becoming a serious social problem in Japan, where the current study was conducted (Ogino, 2004; Saito, 2007; Teo, 2010). The author attempted to systematically assess the efficacy of CBD in a total of 37 18–19-year-old Japanese with SAD, all of whom had been naive to any form of treatment, by measuring the level of the symptoms of SAD with both the Fear of Negative Evaluation Questionnaire (FNE; Watson and Friend, 1969) and the Liebowitz Social Anxiety Scale (LSAS; Liebowitz, 1987) using an exploratory double-blind parallel-group trial experimental paradigm.

NM conceived the study, collected and analyzed the data, and drafted the manuscript.

Liebowitz, M. R. (1987). Social phobia. Mod. Probl. Pharm. Psychiatry 22, 141–173.

Articles published from case reports, case series, or randomized controlled trials on human subjects were included in the review if they examined the safety and efficacy of CBD therapy in anxiety and anxiety-related disorders.

Crystal M. Deas, PharmD, BCPS, Assistant Professor of Pharmacy Practice, McWhorter School of Pharmacy, Samford University, Birmingham, AL

Study selection

Cannabidiol (CBD) has a proposed novel role in the management of anxiety owing to its actions on the endocannabinoid system. The purpose of this systematic review was to evaluate the current evidence on the safety and efficacy of CBD in anxiety and anxiety-related disorders.

CBD has a promising role as alternative therapy in the management of anxiety disorders. However, more studies with standardized approaches to dosing and clinical outcome measurements are needed to determine the appropriate dosing strategy for CBD and its place in therapy.

Zachary Curren, BS, Student Pharmacist, McWhorter School of Pharmacy, Samford University, Birmingham, AL